|
Market Closed -
Nasdaq
16:00:00 2026-08-28 EDT
|
5-day change | 1st Jan Change | ||
| 113.88 USD | -2.61% |
|
-6.85% | +227.24% |
| 08-18 | Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating | MT |
| 07-29 | Corcept Therapeutics Incorporated, Q2 2026 Earnings Call, Jul 29, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- CORT Stock
- Consensus Corcept Therapeutics Incorporated
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
